Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dermatologic bioequivalence

Executive Summary

Bioequivalence for topical dermatological drug products will be discussed by FDA's Pharmaceutical Science Advisory Committee March 12. The agency had issued a draft guidance on dermatopharmacokinetics, but is now considering alternatives (1"The Pink Sheet" Dec. 17, 2001, p. 40). Process Analytical Technologies Subcommittee's final report will also be presented, and the new Manufacturing, Biopharmaceutics and Microbiology subcommittees will be discussed...
Advertisement

Related Content

FDA May Consider DPK Alternatives Following Advisory Committee Meeting
FDA May Consider DPK Alternatives Following Advisory Committee Meeting
Advertisement
UsernamePublicRestriction

Register

PS041120

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel